BioCryst Pharmaceuticals shares rise 1.37% after-hours following the appointment of Babar Ghias as CFO.

Biocryst Pharmaceuticals, Inc. rose 1.37% in after-hours trading, with the company announcing the appointment of Babar Ghias as its new Chief Financial Officer (CFO). Mr. Ghias brings extensive deal-making and operational experience, having previously served as CFO at AvenCell Therapeutics and launched four biotechnology companies focused on rare diseases at Paragon Biosciences. This strategic hire is expected to accelerate the company's path to sustainable growth.